secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001680367-21-000052
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Net loss $17.4M in Q3; cash $290.2M; SL-172154/SL-279252 Phase 1 data; Takeda deal terminated
--------------------------------------------------------------------------------

- Net loss $17.4M ($0.41/share) vs $11.8M ($1.54/share) in Q3 2020; cash $290.2M, down from $335.4M.
- SL-172154 Phase 1 in ovarian cancer well-tolerated with high CD47 occupancy; dose escalation continues to 10mg/kg.
- SL-279252 Phase 1 in solid tumors: one confirmed partial response, stable disease in 12 of 43 patients.
- Shattuck and Takeda mutually terminated collaboration; Shattuck regains full rights to SL-279252 and SL-115154.
- Cash runway sufficient into H2 2024; guidance reduced due to increased SL-172154 clinical and manufacturing costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036721000052/0001680367-21-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036721000052/sttk-20211109.htm
  HTML page:      https://secwatch.observer/filing/0001680367-21-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer